Mutation-Specific Risk in Two Genetic Forms of Type 3 Long QT Syndrome

Judy F. Liu,Arthur J. Moss,Christian Jons,Jesaia Benhorin,Peter J. Schwartz,Carla Spazzolini,Lia Crotti,Michael J. Ackerman,Scott McNitt,Jennifer L. Robinson,Ming Qi,Ilan Goldenberg,Wojciech Zareba
DOI: https://doi.org/10.1016/j.amjcard.2009.08.676
IF: 3.133
2010-01-01
The American Journal of Cardiology
Abstract:The clinical course of patients with 2 relatively common long QT syndrome type 3 mutations has not been well described. In the present study, we investigated the mutational-specific risk in patients with deletional (Delta KPQ) and missense (D1790G) mutations involving the SCN5A gene. The study population involved 50 patients with the Delta KPQ mutation and 35 patients with the D1790G mutation. The cumulative probability of a first cardiac event (syncope, aborted cardiac arrest, or long QT syndrome-related sudden death) was evaluated using the Kaplan-Meier method. The Cox proportional hazards survivorship model was used to determine the independent contribution of clinical and genetic factors to the first occurrence of cardiac events from birth through 40 years of age. The Andersen-Gill proportional intensity regression model was used to analyze the factors associated with recurrent syncope. Patients with a Delta KPQ mutation had a significantly greater probability of a first cardiac event from birth through 40 years of age (34%) than those with the D1790G mutation (20%; p <0.001). Multivariate analysis demonstrated an increased risk of cardiac events among Delta KPQ carriers compared to D1790G carriers (hazard ratio 2.42, p <0.0001) after adjustment for gender and QTc duration. Patients with Delta KPQ mutations also had an increased risk of recurrent syncope (hazard ratio 5.20, p <0.001). In conclusion, the clinical course of patients with long QT syndrome type with Delta KPQ mutations was shown to be more virulent than those with D1790G mutations, and this effect was independent of QTc duration. The findings highlight the importance of knowing the specific mutation in risk stratification of patients with long QT syndrome type 3. (C) 2010 Elsevier Inc. All rights reserved. (Am J Cardiol 2010;105:210-213)
What problem does this paper attempt to address?